Effects of Testosterone Replacement Therapy on Lower Urinary Tract Symptoms: A Systematic Review and Meta-analysis

Taylor P. Kohn, Douglas A. Mata, Ranjith Ramasamy, Larry I. Lipshultz

Research output: Contribution to journalReview article

23 Citations (Scopus)

Abstract

Context There is a potential risk that testosterone replacement therapy (TRT) may exacerbate lower urinary tract symptoms (LUTS) among aging men with late-onset hypogonadism (LOH) because of testosterone's growth-promoting effects on the prostate. Objective To compare the change in LUTS severity as assessed using the International Prostate Symptom Score (IPSS) between men receiving TRT versus placebo for the treatment of LOH. Evidence acquisition Systematic search of MEDLINE, Embase, ClinicalTrials.gov, and The Cochrane Library for randomized controlled trials of TRT for LOH published between January 1992 and September 2015. Studies were eligible for inclusion if they were a randomized control trial, used TRT, and assessed LUTS outcomes using the IPSS. Estimates were pooled using random effects meta-analysis. Differences by study-level characteristics were estimated using meta-regression. Evidence synthesis Data were extracted from 14 trials involving 2029 participants. The average age was 64.5 yr and the average follow-up was 34.4 mo. Seven studies used topical, five used injectable, and two used oral testosterone. There was no statistically significant difference in pooled changes in IPSS from baseline to follow up in men treated with TRT compared with those receiving placebo (-0.41 points [95% confidence interval: -0.89 to 0.07; I2 = 0%, p = 0.28] vs. 0.12 points [95% confidence interval: -0.32 to 0.55; I2 = 0%, p = 0.81], between-group difference p > 0.05). No between-group differences were noted in subanalyses that controlled for potential confounders such as type of testosterone, change in testosterone, aging Male symptom scale, or prostate-specific antigen levels (p > 0.05 for all comparisons). Conclusions In this meta-analysis of 14 clinical trials of TRT for LOH, the change in IPSS was similar among men receiving TRT versus placebo, suggesting that TRT treatment does not worsen LUTS among men with LOH. Patient summary In this analysis of 14 clinical trials, testosterone replacement therapy did not worsen lower urinary tract symptoms among men being treated for late-onset hypogonadism.

Original languageEnglish (US)
Pages (from-to)1083-1090
Number of pages8
JournalEuropean Urology
Volume69
Issue number6
DOIs
StatePublished - Jun 1 2016

Fingerprint

Lower Urinary Tract Symptoms
Testosterone
Meta-Analysis
Hypogonadism
Prostate
Therapeutics
Placebos
Clinical Trials
Confidence Intervals
Prostate-Specific Antigen
MEDLINE
Libraries

Keywords

  • Benign prostatic hyperplasia
  • Hypogonadism
  • Lower urinary tract symptoms
  • Meta-analysis
  • Prostate
  • Testosterone

ASJC Scopus subject areas

  • Urology

Cite this

Effects of Testosterone Replacement Therapy on Lower Urinary Tract Symptoms : A Systematic Review and Meta-analysis. / Kohn, Taylor P.; Mata, Douglas A.; Ramasamy, Ranjith; Lipshultz, Larry I.

In: European Urology, Vol. 69, No. 6, 01.06.2016, p. 1083-1090.

Research output: Contribution to journalReview article

Kohn, Taylor P. ; Mata, Douglas A. ; Ramasamy, Ranjith ; Lipshultz, Larry I. / Effects of Testosterone Replacement Therapy on Lower Urinary Tract Symptoms : A Systematic Review and Meta-analysis. In: European Urology. 2016 ; Vol. 69, No. 6. pp. 1083-1090.
@article{5912250f05e74393bb2f15edb909df64,
title = "Effects of Testosterone Replacement Therapy on Lower Urinary Tract Symptoms: A Systematic Review and Meta-analysis",
abstract = "Context There is a potential risk that testosterone replacement therapy (TRT) may exacerbate lower urinary tract symptoms (LUTS) among aging men with late-onset hypogonadism (LOH) because of testosterone's growth-promoting effects on the prostate. Objective To compare the change in LUTS severity as assessed using the International Prostate Symptom Score (IPSS) between men receiving TRT versus placebo for the treatment of LOH. Evidence acquisition Systematic search of MEDLINE, Embase, ClinicalTrials.gov, and The Cochrane Library for randomized controlled trials of TRT for LOH published between January 1992 and September 2015. Studies were eligible for inclusion if they were a randomized control trial, used TRT, and assessed LUTS outcomes using the IPSS. Estimates were pooled using random effects meta-analysis. Differences by study-level characteristics were estimated using meta-regression. Evidence synthesis Data were extracted from 14 trials involving 2029 participants. The average age was 64.5 yr and the average follow-up was 34.4 mo. Seven studies used topical, five used injectable, and two used oral testosterone. There was no statistically significant difference in pooled changes in IPSS from baseline to follow up in men treated with TRT compared with those receiving placebo (-0.41 points [95{\%} confidence interval: -0.89 to 0.07; I2 = 0{\%}, p = 0.28] vs. 0.12 points [95{\%} confidence interval: -0.32 to 0.55; I2 = 0{\%}, p = 0.81], between-group difference p > 0.05). No between-group differences were noted in subanalyses that controlled for potential confounders such as type of testosterone, change in testosterone, aging Male symptom scale, or prostate-specific antigen levels (p > 0.05 for all comparisons). Conclusions In this meta-analysis of 14 clinical trials of TRT for LOH, the change in IPSS was similar among men receiving TRT versus placebo, suggesting that TRT treatment does not worsen LUTS among men with LOH. Patient summary In this analysis of 14 clinical trials, testosterone replacement therapy did not worsen lower urinary tract symptoms among men being treated for late-onset hypogonadism.",
keywords = "Benign prostatic hyperplasia, Hypogonadism, Lower urinary tract symptoms, Meta-analysis, Prostate, Testosterone",
author = "Kohn, {Taylor P.} and Mata, {Douglas A.} and Ranjith Ramasamy and Lipshultz, {Larry I.}",
year = "2016",
month = "6",
day = "1",
doi = "10.1016/j.eururo.2016.01.043",
language = "English (US)",
volume = "69",
pages = "1083--1090",
journal = "European Urology",
issn = "0302-2838",
publisher = "Elsevier",
number = "6",

}

TY - JOUR

T1 - Effects of Testosterone Replacement Therapy on Lower Urinary Tract Symptoms

T2 - A Systematic Review and Meta-analysis

AU - Kohn, Taylor P.

AU - Mata, Douglas A.

AU - Ramasamy, Ranjith

AU - Lipshultz, Larry I.

PY - 2016/6/1

Y1 - 2016/6/1

N2 - Context There is a potential risk that testosterone replacement therapy (TRT) may exacerbate lower urinary tract symptoms (LUTS) among aging men with late-onset hypogonadism (LOH) because of testosterone's growth-promoting effects on the prostate. Objective To compare the change in LUTS severity as assessed using the International Prostate Symptom Score (IPSS) between men receiving TRT versus placebo for the treatment of LOH. Evidence acquisition Systematic search of MEDLINE, Embase, ClinicalTrials.gov, and The Cochrane Library for randomized controlled trials of TRT for LOH published between January 1992 and September 2015. Studies were eligible for inclusion if they were a randomized control trial, used TRT, and assessed LUTS outcomes using the IPSS. Estimates were pooled using random effects meta-analysis. Differences by study-level characteristics were estimated using meta-regression. Evidence synthesis Data were extracted from 14 trials involving 2029 participants. The average age was 64.5 yr and the average follow-up was 34.4 mo. Seven studies used topical, five used injectable, and two used oral testosterone. There was no statistically significant difference in pooled changes in IPSS from baseline to follow up in men treated with TRT compared with those receiving placebo (-0.41 points [95% confidence interval: -0.89 to 0.07; I2 = 0%, p = 0.28] vs. 0.12 points [95% confidence interval: -0.32 to 0.55; I2 = 0%, p = 0.81], between-group difference p > 0.05). No between-group differences were noted in subanalyses that controlled for potential confounders such as type of testosterone, change in testosterone, aging Male symptom scale, or prostate-specific antigen levels (p > 0.05 for all comparisons). Conclusions In this meta-analysis of 14 clinical trials of TRT for LOH, the change in IPSS was similar among men receiving TRT versus placebo, suggesting that TRT treatment does not worsen LUTS among men with LOH. Patient summary In this analysis of 14 clinical trials, testosterone replacement therapy did not worsen lower urinary tract symptoms among men being treated for late-onset hypogonadism.

AB - Context There is a potential risk that testosterone replacement therapy (TRT) may exacerbate lower urinary tract symptoms (LUTS) among aging men with late-onset hypogonadism (LOH) because of testosterone's growth-promoting effects on the prostate. Objective To compare the change in LUTS severity as assessed using the International Prostate Symptom Score (IPSS) between men receiving TRT versus placebo for the treatment of LOH. Evidence acquisition Systematic search of MEDLINE, Embase, ClinicalTrials.gov, and The Cochrane Library for randomized controlled trials of TRT for LOH published between January 1992 and September 2015. Studies were eligible for inclusion if they were a randomized control trial, used TRT, and assessed LUTS outcomes using the IPSS. Estimates were pooled using random effects meta-analysis. Differences by study-level characteristics were estimated using meta-regression. Evidence synthesis Data were extracted from 14 trials involving 2029 participants. The average age was 64.5 yr and the average follow-up was 34.4 mo. Seven studies used topical, five used injectable, and two used oral testosterone. There was no statistically significant difference in pooled changes in IPSS from baseline to follow up in men treated with TRT compared with those receiving placebo (-0.41 points [95% confidence interval: -0.89 to 0.07; I2 = 0%, p = 0.28] vs. 0.12 points [95% confidence interval: -0.32 to 0.55; I2 = 0%, p = 0.81], between-group difference p > 0.05). No between-group differences were noted in subanalyses that controlled for potential confounders such as type of testosterone, change in testosterone, aging Male symptom scale, or prostate-specific antigen levels (p > 0.05 for all comparisons). Conclusions In this meta-analysis of 14 clinical trials of TRT for LOH, the change in IPSS was similar among men receiving TRT versus placebo, suggesting that TRT treatment does not worsen LUTS among men with LOH. Patient summary In this analysis of 14 clinical trials, testosterone replacement therapy did not worsen lower urinary tract symptoms among men being treated for late-onset hypogonadism.

KW - Benign prostatic hyperplasia

KW - Hypogonadism

KW - Lower urinary tract symptoms

KW - Meta-analysis

KW - Prostate

KW - Testosterone

UR - http://www.scopus.com/inward/record.url?scp=84961656623&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84961656623&partnerID=8YFLogxK

U2 - 10.1016/j.eururo.2016.01.043

DO - 10.1016/j.eururo.2016.01.043

M3 - Review article

C2 - 26874809

AN - SCOPUS:84961656623

VL - 69

SP - 1083

EP - 1090

JO - European Urology

JF - European Urology

SN - 0302-2838

IS - 6

ER -